Figure 4.

Treatment with the fusion vaccine in combination with PD1/TIM3/RGMb blockade prevents establishment of acute myeloid leukemia upon re-challenge with tumor cells. Ninety days after the initial tumor challenge and treatment with six doses of anti-PD1/TIM3/RGMb (mAbs), C57BL/6J mice (n=5) were challenged with an additional dose of 50,000 luciferase/mCherry-transduced syngeneic TIB-49 cells. Naive, age-matched mice (n=5) were inoculated with the same dose as controls. To assess AML burden, (A) bioluminescence imaging was performed after re-challenge and (B) the mice were followed for survival for 90 days, as illustrated in a Kaplan-Meier curve.